医学
凝血病
抗纤维溶解
低温沉淀
纤溶
抑肽酶
纤维蛋白原
纤维蛋白
抗凝血酶
止血
纤溶亢进
麻醉
弥漫性血管内凝血
血栓弹性成像
凝结
重症监护医学
氨甲环酸
外科
免疫学
内科学
肝素
失血
作者
Daniel Bolliger,Klaus Görlinger,Kenichi A. Tanaka,David S. Warner
出处
期刊:Anesthesiology
[Ovid Technologies (Wolters Kluwer)]
日期:2010-09-30
卷期号:113 (5): 1205-1219
被引量:316
标识
DOI:10.1097/aln.0b013e3181f22b5a
摘要
Fluid resuscitation after massive hemorrhage in major surgery and trauma may result in extensive hemodilution and coagulopathy, which is of a multifactorial nature. Although coagulopathy is often perceived as hemorrhagic, extensive hemodilution affects procoagulants as well as anticoagulant, profibrinolytic, and antifibrinolytic elements, leading to a complex coagulation disorder. Reduced thrombin activation is partially compensated by lower inhibitory activities of antithrombin and other protease inhibitors, whereas plasma fibrinogen is rapidly decreased proportional to the extent of hemodilution. Adequate fibrinogen levels are essential in managing dilutional coagulopathy. After extensive hemodilution, fibrin clots are more prone to fibrinolysis because major antifibrinolytic proteins are decreased.Fresh frozen plasma, platelet concentrate, and cryoprecipitate are considered the mainstay hemostatic therapies. Purified factor concentrates of plasma origin and from recombinant synthesis are increasingly used for a rapid restoration of targeted factors. Future clinical studies are necessary to establish the specific indication, dosing, and safety of novel hemostatic interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI